Arash Kiarash
Internal Medicine · Taylor, MINPI 1003921891
Payments from drug & device makers
Across 180 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$566
- GSK$504
- Merck$377
- Sunovion Pharmaceuticals Inc.$349
- Lilly USA, LLC$172
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$138
- plus $811 from 16 others
What the payments were for
- Food & beverage$2,915100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $566 |
| GSK | 47 | $504 |
| Merck | 18 | $377 |
| Sunovion Pharmaceuticals Inc. | 27 | $349 |
| Lilly USA, LLC | 11 | $172 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $138 |
| Pfizer | 9 | $137 |
| Novartis | 7 | $117 |
| AbbVie | 6 | $101 |
| Neurelis, Inc. | 4 | $99 |
| Biogen | 4 | $71 |
| Sumitomo Pharma America, Inc. | 5 | $67 |
| Amgen | 3 | $51 |
| Novo Nordisk | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Boston Scientific | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Ardelyx, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$2,915 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 452 | $199,492 |
| JardianceEmpagliflozin | 171 | $133,953 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $117,467 |
| VraylarCariprazine Hcl | 59 | $83,148 |
| FarxigaDapagliflozin Propanediol | 127 | $76,371 |
| MounjaroTirzepatide | 60 | $62,015 |
| LinzessLinaclotide | 86 | $56,599 |
| TrulicityDulaglutide | 43 | $40,981 |
| XareltoRivaroxaban | 53 | $39,119 |
| JanuviaSitagliptin Phosphate | 61 | $37,378 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 61 | $36,961 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $24,326 |
| AptiomEslicarbazepine Acetate | 15 | $18,786 |
| EntrestoSacubitril/Valsartan | 18 | $14,637 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $14,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $137 | $199,492452 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $504 | $152,842240 claims |
| AbbVieVraylar, Linzess | $101 | $139,748145 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Bevespi Aerosphere | $566 | $127,550230 claims |
| Lilly USA, LLCMounjaro, Trulicity | $172 | $102,996103 claims |
| MerckJanuvia | $377 | $37,37861 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $349 | $18,78615 claims |
| NovartisEntresto | $117 | $14,63718 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $18 | $12,16430 claims |
| Novo NordiskOzempic | $26 | $10,86411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Taylor
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.